Year | First author | Type of study | Number and type of patients considered | Patients with splenic metastases from NPC | Methods of detection | Surgery performed | Confirmatory histology of NPC splenic metastases | Relapse and survival rates |
---|---|---|---|---|---|---|---|---|
1952 | Abrams et al. [5] | CS | 1000 patients with splenic metastases from carcinomas | 3 (0.3 %) | Autopsy | NS | NS | NS |
1989 | Siniluoto et al. [37] | CS | 31 patients with splenic metastases | 1 (3.2 %) | US | NS | NS | NS |
2000 | Wan et al. [39] | CS | 53 patients with focal splenic lesions | 2 (3.7 %) | US | NS | NS | NS |
2000 | Lam & Tang [3] | CS | 92 patients with splenic metastases | 4 (4.3 %) | NS | NS | UCNT | NS |
2001 | Gacani et al. [30] | CS | 65 patients with NPC and DM | 1 (1.5 %) | US | NS | NS | DM within 24 months after therapy |
2004 | Cho et al. [29] | CS | 31 patients with recurrent type 2 NPC | 1 (3.2 %) | NS | NS | NS | NS |
2010 | Radhakrishnan et al. [36] | CR | 1 pediatric patient with UCNT | 1 | FDG-PET/CT | NS | NS | Death after 90 days of chemotherapy |
2010 | Ng et al. [35] | CS | 179 NPC patients at high risk of residual disease or with suspected recurrence | 1 (0.5 %) | WB-MRI and FDG-PET/CT | NS | NS | NS |
2011 | Gatenby et al. [31] | CS | 21 patients undergone splenectomies for DM | 1 (4.7 %) | NS | Primary tumor, radical neck dissection and synchronous splenectomy | SCC | DFS: 1 year 10 month OS: 2 years 3 months |
2013 | Hsieh et al. [32] | CS | 22 patients with non-keratinizing or undifferentiated NPC | 1 (4.6 %) | US, CT or MRI | NS | NS | Median time to PD: 10 months; Median OS: 16 months |
2015 | Mak et al. [34] | CS | 558 patients with NPC | 1 (0.2 %) | CT and PET/CT | NS | NS | 10.8–18.4 months before DF; Mean DSS in patients with DM: 31.2 months (95 % CI 20.9–41.6) Mean OS in patients with DM: 28.2 months (95 % CI 19.3–37.1) |
2015 | Ma et al. [33] | CS | 2 pediatric patients with NPC | 1 | FDG-PET/CT | NS | NS | NS |
2015 | Al Tamimi et al. [28] | CS | 352 patients with NPC and DM | 4 (1.1 %) | FDG-PET/CT | NS | NS | NS |